以岭药业：全资子公司获得盐酸伐昔洛韦片注册证书

Core Viewpoint - Yiling Pharmaceutical's wholly-owned subsidiary, Yiling Wanzhou, has obtained the registration certificate for Acyclovir Hydrochloride Tablets (0.5g), allowing it to sell in the domestic market [1]. Group 1: Approval Status - The product has been classified as a Class 4 chemical drug and is now qualified for domestic market sales [1]. Group 2: Product Information - Indications include treatment for shingles, herpes simplex virus infections, and prevention of recurrence [3]. - The product is included in the National Medical Insurance Directory as a Class B variety [3]. - The domestic market size for Acyclovir is expected to reach 450 million yuan by 2025, with a sales volume of 130 million tablets, capturing 3.17% of the antiviral drug market [3]. Group 3: Additional Information - The product is a dual-filing variety in both China and the U.S., having received FDA approval in March 2020 [2]. - The company notes that this product will not have a significant impact on current performance and emphasizes the need to monitor market policies and competitive risks [2].